Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 16/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23860586 | 0.88 | GRIN2B (0.48) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL29132176 | 0.85 | GRIN2B (0.48) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL25293557 | 0.81 | GRM5 (0.54) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL29132210 | 0.80 | GRIN2B (0.48) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL23860670 | 0.80 | GRIN2B (0.41) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL26926574 | 0.80 | SMN1; SMN2 (0.57) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL23860615 | 0.80 | SMN1; SMN2 (0.57) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL30183454 | 0.78 | MAPT (0.40) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL23860611 | 0.78 | MAPT (0.40) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL31639486 | 0.77 | SMN1; SMN2 (0.47) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473294-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240158405-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4121167-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115605267-A | Selective modulators of mutant LRRK2 proteolysis and related methods of use | 阿维纳斯企业公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20220064168-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-03-03 | — | — | US | disclosed |
| WO-2021194878-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158405-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | LRRK2, ADRM1, CRBN | GRIN2B 596/4885CYP2D6 4738/4885CYP2C9 4823/4885 |
| US-20220064168-A1 | SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | LRRK2, ADRM1, CRBN | GRIN2B 596/4885CYP2D6 4738/4885CYP2C9 4823/4885 |
| US-12473294-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | GRIN2B 596/4885CYP2D6 4738/4885CYP2C9 4823/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | GRIN2B 596/4885CYP2D6 4738/4885CYP2C9 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.